MXPA04000993A - MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. - Google Patents

MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO.

Info

Publication number
MXPA04000993A
MXPA04000993A MXPA04000993A MXPA04000993A MXPA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A
Authority
MX
Mexico
Prior art keywords
nitric oxide
mammalian cells
mammals
pulmonary disease
indigenous
Prior art date
Application number
MXPA04000993A
Other languages
English (en)
Inventor
Martin Alain
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of MXPA04000993A publication Critical patent/MXPA04000993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a un metodo para tratar una enfermedad pulmonar en mamiferos mediante la alteracion in vivo de los niveles normales del oxido nitrico en celulas de mamiferos. El metodo comprende contactar las celulas de mamiferos con una cantidad terapeuticamente efectiva de un mediador de oxido nitrico seleccionado del grupo que consiste de piruvatos, precursores de piruvato, a-ceto acidos que tiene cuatro o mas atomos de carbono, precursores de a-ceto acidos que tienen cuatro o mas atomos de carbono y las sales de los mismos. El metodo ademas comprende contactar las celulas de mamiferos con un agente terapeutico y una fuente de oxido nitrico seleccionada del grupo que consiste de oxido nitrico, precursores del oxido nitrico y estimuladores del oxido nitrico. En otra modalidad, el metodo comprende tratar una enfermedad pulmonar en mamiferos mediante proteger los niveles normales in vivo del oxido nitrico en las celulas de mamiferos durante la inhalacion de ozono mediante contactar las celulas de mamiferos con una cantidad terapeuticamente efectiva de un mediador de oxido nitrico.
MXPA04000993A 2001-08-21 2002-08-15 MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. MXPA04000993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31387201P 2001-08-21 2001-08-21
PCT/US2002/026060 WO2003017996A1 (en) 2001-08-21 2002-08-15 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide

Publications (1)

Publication Number Publication Date
MXPA04000993A true MXPA04000993A (es) 2004-04-20

Family

ID=23217517

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000993A MXPA04000993A (es) 2001-08-21 2002-08-15 MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO.

Country Status (8)

Country Link
US (1) US6689810B2 (es)
EP (1) EP1427402A4 (es)
JP (1) JP2005501106A (es)
AU (1) AU2002329762B2 (es)
CA (1) CA2457983C (es)
IL (1) IL159898A0 (es)
MX (1) MXPA04000993A (es)
WO (1) WO2003017996A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20080213403A1 (en) * 2002-07-25 2008-09-04 Alain Martin Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
CN100418519C (zh) * 2002-09-24 2008-09-17 三得利株式会社 用于增强认知能力的含有花生四烯酸或其与二十二碳六烯酸的组合的组合物
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
CA2413834A1 (en) 2002-12-10 2004-06-10 1017975 Alberta Limited Nitric oxide gas generator
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
EP1701747B1 (en) 2004-01-07 2014-03-12 Noxilizer, Inc. Sterilisation method
US8017074B2 (en) 2004-01-07 2011-09-13 Noxilizer, Inc. Sterilization system and device
JP2007526316A (ja) * 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
US20080008771A1 (en) * 2004-05-27 2008-01-10 Children's Hospital Medical Center Nitric Oxide Dioxygenase Inhibitors
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1915157A4 (en) 2005-08-02 2010-09-01 Nicox Sa NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
WO2007101068A2 (en) * 2006-02-22 2007-09-07 Puricore, Inc. Methods of treating cystic fibrosis
WO2007126609A1 (en) 2006-03-29 2007-11-08 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US9675569B2 (en) * 2007-08-08 2017-06-13 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
KR20170005155A (ko) * 2008-01-31 2017-01-11 반더빌트유니버시티 폐의 용태에 따른 치료 방법
AU2009212693B2 (en) 2008-01-31 2014-05-01 Vanderbilt University Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
US20100040703A1 (en) * 2008-08-13 2010-02-18 Chris Miller Use of nitric oxide
AU2009292963B2 (en) * 2008-09-22 2016-08-18 VERO Biotech LLC. Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
EP2361099B1 (en) 2009-02-23 2012-09-12 Noxilizer, Inc. Method for gas sterilization
JP6263540B2 (ja) 2012-09-19 2018-01-17 グレスポ・アクチボラゲットＧｒｅｓｐｏ ＡＢ 脳機能向上用組成物
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
EP3195168B1 (en) * 2014-07-31 2022-09-07 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
US20200237815A1 (en) * 2017-02-24 2020-07-30 Alain Martin Methods for treatment of lung damage and for inhibition of lung fibrosis
US11311505B2 (en) * 2017-02-24 2022-04-26 Cellular Sciences, Inc. Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
WO2021023263A1 (zh) * 2019-08-06 2021-02-11 连云港金康和信药业有限公司 产生安全量的一氧化氮的药物组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
AU719332B2 (en) * 1995-09-19 2000-05-04 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response

Also Published As

Publication number Publication date
EP1427402A1 (en) 2004-06-16
IL159898A0 (en) 2004-06-20
CA2457983C (en) 2011-09-06
CA2457983A1 (en) 2003-03-06
JP2005501106A (ja) 2005-01-13
US6689810B2 (en) 2004-02-10
US20030040542A1 (en) 2003-02-27
WO2003017996A1 (en) 2003-03-06
AU2002329762B2 (en) 2007-03-01
EP1427402A4 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
MXPA04000993A (es) MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO.
GB0004153D0 (en) Novel use
MXPA03010142A (es) Nuevos derivados de arilheteroalquilamina.
MXPA03008223A (es) Compuesto para tratamiento de enfermedades inflamatorias.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
NZ545506A (en) Therapeutic agents useful for treating pain
HUP0300833A2 (hu) Gabapentin analogonok alvászavarok kezelésére
SE9803518D0 (sv) Novel compounds
NZ510920A (en) Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
AU2003278667A1 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
SE9803773D0 (sv) Compounds
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
SE0004101D0 (sv) New use
NZ519722A (en) Treatment of diabetic ulcers
WO2003049667A3 (en) The method of treating cancer
GB0004152D0 (en) Novel compounds
MY131690A (en) 6-[triazolyl[3-(trifluoromethyl) phenyl]methyl]-2- quinolinones and -quinolinethiones
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
SE0102641D0 (sv) Novel compounds
MXPA03011193A (es) Nuevos compuestos utiles en enfermedad de reflujo.
CA2328348A1 (en) 2-methylpropionic acid derivatives and medicinal compositions containing the same
SE0102639D0 (sv) Novel compounds
SE0102640D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FG Grant or registration